紧急ABO血型不合的活体肝移植治疗Wilson病引起的急性肝衰竭。

IF 0.6 Q4 HEMATOLOGY
Asian Journal of Transfusion Science Pub Date : 2023-01-01 Epub Date: 2022-05-26 DOI:10.4103/ajts.ajts_55_21
Joseph J Valamparampil, Deepti Sachan, Naresh Shanmugam, Srinivas Mettu Reddy, Mohamed Rela
{"title":"紧急ABO血型不合的活体肝移植治疗Wilson病引起的急性肝衰竭。","authors":"Joseph J Valamparampil,&nbsp;Deepti Sachan,&nbsp;Naresh Shanmugam,&nbsp;Srinivas Mettu Reddy,&nbsp;Mohamed Rela","doi":"10.4103/ajts.ajts_55_21","DOIUrl":null,"url":null,"abstract":"<p><p>We report the clinical outcome of an emergency ABO incompatible-liver transplantation (LT) for an 8-year-old child with Wilson's disease-induced acute liver failure. The pretransplant anti-A antibody titer was 1:64, and hence he underwent three cycles of conventional plasma exchange as pretransplant liver supportive treatment for deranged coagulopathy and liver function followed by one cycle of immunoadsorption (IA) prior to LT. The posttransplant immunosuppression consisted of rituximab, tacrolimus, mycophenolate mofetil, and corticosteroid. The patient had anti-A isoagglutinin rebound with elevated aminotransferases levels from postoperative day 7 for which he was restarted on IA plasmapheresis, but antibody titers did not decrease. Hence, he was switched to conventional plasmapheresis (CP) with which anti-A antibody titers decreased. The total dose of rituximab (150 milligrams/square meter of body surface area) was given in two divided doses of 75 mg at D-1 and D + 8 which was much less than the dose conventionally advocated (375 milligrams/square meter of body surface area). He is clinically well with good graft function without rejection after 1 year of follow-up. This case illustrates that IA and CP in conjunction with adequate immunosuppression is a viable approach in emergency ABO-incompatible-LT in Wilson disease-induced acute liver failure.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"17 1","pages":"128-130"},"PeriodicalIF":0.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/87/AJTS-17-128.PMC10180780.pdf","citationCount":"0","resultStr":"{\"title\":\"Emergency ABO-incompatible living donor liver transplantation in Wilson disease-induced acute liver failure.\",\"authors\":\"Joseph J Valamparampil,&nbsp;Deepti Sachan,&nbsp;Naresh Shanmugam,&nbsp;Srinivas Mettu Reddy,&nbsp;Mohamed Rela\",\"doi\":\"10.4103/ajts.ajts_55_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We report the clinical outcome of an emergency ABO incompatible-liver transplantation (LT) for an 8-year-old child with Wilson's disease-induced acute liver failure. The pretransplant anti-A antibody titer was 1:64, and hence he underwent three cycles of conventional plasma exchange as pretransplant liver supportive treatment for deranged coagulopathy and liver function followed by one cycle of immunoadsorption (IA) prior to LT. The posttransplant immunosuppression consisted of rituximab, tacrolimus, mycophenolate mofetil, and corticosteroid. The patient had anti-A isoagglutinin rebound with elevated aminotransferases levels from postoperative day 7 for which he was restarted on IA plasmapheresis, but antibody titers did not decrease. Hence, he was switched to conventional plasmapheresis (CP) with which anti-A antibody titers decreased. The total dose of rituximab (150 milligrams/square meter of body surface area) was given in two divided doses of 75 mg at D-1 and D + 8 which was much less than the dose conventionally advocated (375 milligrams/square meter of body surface area). He is clinically well with good graft function without rejection after 1 year of follow-up. This case illustrates that IA and CP in conjunction with adequate immunosuppression is a viable approach in emergency ABO-incompatible-LT in Wilson disease-induced acute liver failure.</p>\",\"PeriodicalId\":42296,\"journal\":{\"name\":\"Asian Journal of Transfusion Science\",\"volume\":\"17 1\",\"pages\":\"128-130\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/87/AJTS-17-128.PMC10180780.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Journal of Transfusion Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ajts.ajts_55_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/5/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Transfusion Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ajts.ajts_55_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

我们报告了一例8岁Wilson病引起的急性肝衰竭患儿进行紧急ABO血型不合肝移植(LT)的临床结果。移植前抗A抗体滴度为1:64,因此他接受了三个周期的常规血浆交换,作为移植前对凝血障碍和肝功能的肝支持治疗,然后在LT前进行一个周期的免疫吸附(IA)。移植后免疫抑制包括利妥昔单抗、他克莫司、霉酚酸酯和皮质类固醇。患者从术后第7天开始进行IA血浆置换,出现抗A同种凝集素反弹,转氨酶水平升高,但抗体滴度没有下降。因此,他转而使用常规血浆置换术(CP),从而降低抗A抗体滴度。利妥昔单抗的总剂量(150毫克/平方米体表面积)在D-1和D+8分两次给药,剂量为75毫克,远低于传统提倡的剂量(375毫克/平方米体表面积)。经过一年的随访,他临床表现良好,移植物功能良好,无排斥反应。该病例表明,IA和CP结合适当的免疫抑制是治疗Wilson病诱导的急性肝衰竭中紧急ABO不相容LT的可行方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Emergency ABO-incompatible living donor liver transplantation in Wilson disease-induced acute liver failure.

Emergency ABO-incompatible living donor liver transplantation in Wilson disease-induced acute liver failure.

We report the clinical outcome of an emergency ABO incompatible-liver transplantation (LT) for an 8-year-old child with Wilson's disease-induced acute liver failure. The pretransplant anti-A antibody titer was 1:64, and hence he underwent three cycles of conventional plasma exchange as pretransplant liver supportive treatment for deranged coagulopathy and liver function followed by one cycle of immunoadsorption (IA) prior to LT. The posttransplant immunosuppression consisted of rituximab, tacrolimus, mycophenolate mofetil, and corticosteroid. The patient had anti-A isoagglutinin rebound with elevated aminotransferases levels from postoperative day 7 for which he was restarted on IA plasmapheresis, but antibody titers did not decrease. Hence, he was switched to conventional plasmapheresis (CP) with which anti-A antibody titers decreased. The total dose of rituximab (150 milligrams/square meter of body surface area) was given in two divided doses of 75 mg at D-1 and D + 8 which was much less than the dose conventionally advocated (375 milligrams/square meter of body surface area). He is clinically well with good graft function without rejection after 1 year of follow-up. This case illustrates that IA and CP in conjunction with adequate immunosuppression is a viable approach in emergency ABO-incompatible-LT in Wilson disease-induced acute liver failure.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
56
审稿时长
44 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信